Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

Weiming Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7870-6968; OpenAlex author ID A5066584624. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: none · 2022: 2 papers

Papers 11

  1. Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s10238-021-00785-x↗
  2. Down-regulation of USP22 reduces cell stemness and enhances the sensitivity of pancreatic cancer cells to cisplatin by inactivating the Wnt/β-catenin pathway. Co-author DOI 10.1016/j.tice.2022.101787↗
  3. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000019504↗
  4. miR-25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2. Last author DOI 10.3892/etm.2020.8595↗
  5. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Last author DOI 10.1038/s41598-018-37617-0↗
  6. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Last author DOI 10.1042/bsr20181374↗
  7. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling. Last author DOI 10.3892/mmr.2019.10699↗
  8. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-β pathway activation. Last author DOI 10.3892/ol.2019.10111↗
  9. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. Last author DOI 10.1016/j.yexcr.2017.10.033↗
  10. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Co-author DOI 10.18632/oncotarget.22494↗
  11. [Effects of RAGE on Cell Proliferation and Tumor Growth in Pancreatic Cancer]. Last author PMID 28612557↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huimin Lü · 8 shared papers, 2017–2022 · strength 1.03
  2. Li Mao · 6 shared papers, 2019–2022 · strength 0.76
  3. DuJiang Yang · 5 shared papers, 2019–2020 · strength 0.55
  4. Zhenlu Li · 2 shared papers, 2022 · strength 0.41
  5. Junjie Xiong · 3 shared papers, 2017–2019 · strength 0.24
  6. Xing Huang · 1 shared paper, 2022 · strength 0.22
  7. Zihe Wang · 1 shared paper, 2022 · strength 0.19
  8. Xu-Bao Liu · 2 shared papers, 2017 · strength 0.13
  9. Ailin Wei · 2 shared papers, 2017 · strength 0.13
  10. Dan Wang · 2 shared papers, 2017 · strength 0.13
  11. Xubao Liu · 1 shared paper, 2020 · strength 0.13
  12. Li Wang · 1 shared paper, 2020 · strength 0.13
  13. Bole Tian · 1 shared paper, 2020 · strength 0.13
  14. Ling Zhang · 1 shared paper, 2019 · strength 0.11
  15. Zhaoda Zhang · 1 shared paper, 2017 · strength 0.10
  16. Weiwei Chen · 1 shared paper, 2017 · strength 0.10
  17. Nengwen Ke · 1 shared paper, 2017 · strength 0.07
  18. Ang Li · 1 shared paper, 2017 · strength 0.06
  19. Chunlu Tan · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.